

شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو

بسم الله الرحمن الرحيم





HANAA ALY



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرونيله



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية التوثيق الإلكترونى والميكروفيلم

جامعة عين شمس التوثيق الإلكتروني والميكروفيلم قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها على هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY

Evaluation of plasma M2-Pyruvate Kinase as a novel biomarker in the differentiation between Functional and Organic Colonic Disorders

Thesis

Submitted for Partial Fulfillment of M.D. Degree
In Internal Medicine

By Islam Adel Awaad Elsayed

M.B.B.Ch & M.Sc.

Under Supervision of

Prof. Dr./ Tarek Mohamed Youssef

Professor of Internal Medicine and Gastroenterology Faculty of Medicine, Ain Shams University

Prof. Dr./ Wael Ahmed Yousry

Professor of Internal Medicine and Gastroenterology Faculty of Medicine, Ain Shams University

Dr./ Mohamed Magdy Salama

Lecturer of Internal Medicine and Gastroentrology Faculty of Medicine, Ain Shams University

Dr./ Ahmed EL Metwally Ahmed

Lecturer of Internal Medicine and Gastroentrology Faculty of Medicine, Ain Shams University

Faculty of Medicine
Ain Shams University
2020





First and *foremost*, I feel always indebted to Allah, the Most Beneficent and Merciful who gave me the strength to accomplish this work,

My deepest gratitude to my supervisor, Prof. Dr./ Tarek Mohamed Youssef, Professor of Internal Medicine and Gastroenterology, Faculty of Medicine, Ain Shams University, for his valuable guidance and expert supervision, in addition to his great deal of support and encouragement. I really have the honor to complete this work under his supervision. God blesses him and keeps him a sun lightening the way for the scientific students.

I would like to express my great and deep appreciation and thanks to Prof. Dr./ Wael Ahmed Yousry, Professor of Internal Medicine and Gastroenterology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, his patience and granting me much of his time in reviewing and correcting this work.

I would like also to thank with all appreciation **Dr./ Mohamed Magdy Salama,** Lecturer of Internal Medicine and Gastroentrology, Faculty of Medicine, Ain Shams University, for the efforts and time he has devoted to accomplish this work.

No workds can express my gratitude to **Dr./ Ahmed EL Metwally Ahmed,** Lecturer of Internal Medicine and Gastroentrology, Faculty of Medicine, Ain Shams University, for this close supervison, monitoring and fruiteful direction druing the whole work.

My special thanks and deep appreciation to **Prof Dr./ Ashraf Zaky,** Senior consultant of Gastroentrology of military hospitals for his great support and encouragement throughout this work.

Special thanks to my Parents and all my **Family** members, specially my **Parents** and my **Wife**, for their continuous encouragement, enduring me and standing by me.



List of Contents

Subject	Page No.
List of Abbreviations	i
List of Tables	vi
List of Figures	ix
Introduction	1
Aim of the Work	4
Review of Literature	
M2-Pyruvate Kinase	5
Functional Bowel Disorders	16
Inflammatory bowel disease	38
Colorectal polyps	63
Colorectal cancer	80
Patients and Methods	111
Results	123
Discussion	159
Summary	181
Conclusions	187
Recommendations	188
References	189
Arabic Summary	

List of Abbreviations

Abbr. **Full-term** 5-ASAs : 5-Aminosalicylates : 5-Fluorouracil 5-FU **6-MP** : 6-Mercaptopurine American College of Gastroenterology ACG **ACR** American College of Radiology ACS **American Cancer Society** Adenosine diphosphate ADP **AFAP** Attenuated familial adenomatous polyposis **AFP** Alpha-fetoprotein American Gastroenterology Association **AGA AJCC** American Joint Commission on Cancer Alanine aminotransferase **ALT** Antineutrophil cytoplasmic antibodies ANCA Anti-Anti-tumor necrosis factor TNF APC : Adenomatous polyposis coli **ASCA** Anti-Saccharomyces cerevisiae antibodies **AST** : Aspartate aminotransferase ATP : Adenosine triphosphate AUC Area under the curve AZA Azathioprine : Bristol Stool Form Scale **BSFS BSG** British Society of Gastroenterology **CA19-9** Carbohydrate antigen 19-9 Complete blood count **CBC** CD Crohn's disease

: Carcionemberyonic antigen

Computed tomography

: CpG island methylator phenotype

: Confidence interval

Colorectal cancerC-reactive protein

CEA

CRC

CRP CT

CI CIMP CTC : Computed tomographic colonographycTNM : Clinical tumor-node-metastasis staging

DALM : Dysplastic associated lesion massDCBE : Double contrast barium enema

DKDKK-3Dickkopf-3

DNA : Deoxyribo-nucleic acid

ECM : Extra-intestinal manifestations
 EDTA : Ethylenediamine tetra-acetic acid
 EGER : Epidermal growth factor receptor
 ELIZA : Enzyme-linked immunosorbent assay

EMR : Endoscopic Mucosal Resection

ESD : Endoscopic Sub mucosal Dissection

ESR : Erythrocyte sedimentation rate
FAP : Familial adenomatous polyposis

FBD : Functional bowel disorders **FBP** : Fructose 1,6-bisphosphate

FBS: Fasting blood sugar

FCCX: Familial colorectal cancer type X
 FDA: Food and Drug Administration
 FIT: Fecal immunochemical test
 FSIG: Flexible sigmoidoscopy

FUC : AFucosidaseGAL : βDgalactosidase

gFOBT: guaiac-based fecal occult blood test

GIT : Gastrointestinal tract

GMA : Granulocyte monocyte apheresis

H & E : Haematoxylin & Eosin

Hb : Haemoglobin

HEX : N-acetyl β Dhexosaminidase

HEX A : N-acetyl β Dhexosaminidase isoenzymes A
HEX B : N-acetyl β Dhexosaminidase isoenzymes B

HIF-1: Hypoxic inducing factor 1

HNPCC: Hereditary nonpolyposis colorectal cancer

HP : Hyperplastic polyps

HPS: Hamartomatous polyposis syndromes

HRAs
High-risk adenomas
HRP
Horseradish Peroxidase
IBD
Inflammatory bowel disease
IBS
Irritable bowel syndrome

IBS-C: Irritable bowel syndrome with predominant

constipation

IBS-D : Irritable bowel syndrome with predominant

diarrhea

IBS-M: Irritable bowel syndrome with mixed bowel habits

IBS-U: Irritable bowel syndrome unclassified

IGFBP-2: Insulin like growth factor binding protein 2

INR : International normalized ratio

IQR : Inter-quartile range

JPS : Juvenile polyposis syndrome
 LDHA : Lactate dehydrogenase A
 lncRNA : Long non-coding RNA
 LRAs : Low-risk adenomas

M : Metastasis

M1-PK : M1-pyruvate kinase isoformM2-PK : M2-pyruvate kinase isoform

MAN : Amannosidase

MAP : MUTYH-associated polyposis

miRNA : MicroRNA

MMR : Mismatch repair

MRI : Magnetic resonance imaging

mRNA : Messenger RNA

mTOR : Mammalian target of rapamycin

MUTYH : MUTY homolog geneN : Lymph node metastasis

NCCN : National Comprehensive Cancer Network

NMCD : Non-malignant colorectal disease

NPV : Negative predictive value

NSAIDs : Non-steroidal anti-inflammatory drugsNTIMP- : N-methyltransferase and tissue inhibitor of

1 metalloproteinsases-1

OD : Optical density

PAB : Pancreatic autoantibodies

PDK-1: Pyruvate dehydrogenase kinase 1

PEP: Phosphoenol pyruvate

PET : Positron emission tomography

PHD-3 : Prolyl hydroxylase 3

PHTS: PTEN-hamartoma tumor syndromes

PI3K : Phosphatidylinositol 3 kinase

PJS: Peutz-Jeghers syndrome

PKL: Pyruvate kinase isoform in the liver

PKR: Pyruvate kinase isoform in the red blood cells

PLT : Platelets

PPV : Positive predictive value
 ProTa : Phosphorylate prothymosin
 PSC : Primary sclerosing cholangitis

PSL: Prednisolone

PTEN: Phosphatase and tensin homolog

pTNM: Pathological tumor- node- metastasis stage

R : Correlation coefficient

RNA : Ribonucleic acid

ROC : Receiver operating characteristic

RTK : Receptor tyrosine kinase

SAPS : SalazosulfapyridineSD : Standard deviation

sDNA : Stool DNA

SOCS-3: Suppressor of cytokine signaling 3

SPS : Serrated polyposis syndrome

SPSS : Statistical Package for Social Science

SSA/P : Sessile serrated adenoma/polyps

STK : Serine-threonine kinaseT : Tumor depth of invasion

TAG72 : Tumor associated glycoprotein 72
 TGF-β : Transforming growth factor beta

TMB : Tetramethylbenzidine

TNM: Tumor-lymph node-metastasisTPS: Tissue polypeptide specific antigen

TSA/P : Traditional serrated adenomas/polyps

UC : Ulcerative colitisUS : United State

USMSTF: United State Multi-Society Task Force

USPSTF: United State Preventive Services Task Force

VEGF: Vascular endothelial growth factor

WBC : White blood cell countWHO : Would health organization

List of Tables

Table No	Title	Page No.
Table (1):	Functional bowel disorders classif (Rome IV criteria)	
Table (2):	Comparison of symptom-based criter	ia32
Table (3):	Distribution of ulcerative colitis	42
Table (4):	Montreal classification of disease se in ulcerative colitis	-
Table (5):	Diagnostic features of ulcerative colitis	s44
Table (6):	Summary of Montreal and classification of Crohn's disease	
Table (7):	Features of CD	49
Table (8):	Extra-intestinal Manifestations of IBI	D 53
Table (9):	Currently used CRC screening tests	99
Table (10):	Sensitivity of CRC Screening Tests	100
Table (11):	Categories for Risk for Deve Colorectal Cancer	
Table (12):	Summary of CRC Screening Guidelin Average- Risk Persons	
Table (13):	Surveillance and screening Guideling Persons at Increased Risk of CRC	
Table (14):	Surveillance and screening Guideling Persons at High Risk of CRC	
Table (15):	Comparison between the Studied Gro Regard age and sex	oups as

Table (16):	Comparison between the Studied Groups as Regard main clinical presentation
Table (17):	Comparison between the Studied Groups as Regard ESR and CRP
Table (18):	Comparison between the Studied Groups as Regard laboratory data (CBC, liver functions and renal functions)
Table (19):	Comparison between the Studied Groups as Regard CEA, CA19-9 and plasma M2 PK 133
Table (20):	Comparison between the Studied Groups as Regard stool analysis and FOBT 135
Table (21):	Comparison between the Studied Groups as Regard imaging
Table (22):	Comparison between the Studied Groups as Regard colonoscopy, histopathology and grading
Table (23):	Correlations between Plasma M2 PK level and other parameters in all cases
Table (24):	Relations between Plasma M2 PK level and other parameters in all cases
Table (25):	Relations between Plasma M2 PK level and IBD group as regard colonoscopy finding 144
Table (26):	Relations between Plasma M2 PK level and (IBD, colorectal polyps and CRC groups) as regard histopathological finding
Table (27):	Relations between Plasma M2 PK level and (colorectal polyps and CRC groups)as regard grading

Table (28):	Diagnostic performance of CEA and Plasma M2-PK in Discrimination between IBS and IBD Groups
Table (29):	Diagnostic performance of CEA and Plasma M2-PK in Discrimination between IBS and colorectal polyps Groups
Table (30):	Diagnostic performance of CEA and Plasma M2-PK in Discrimination between IBS and CRC Groups
Table (31):	Diagnostic performance of Plasma M2-PK in Discrimination between IBD and colorectal polyps Groups
Table (32):	Diagnostic performance of CEA and Plasma M2-PK in Discrimination of IBD and CRC Groups
Table (33):	Diagnostic performance of CEA and Plasma M2-PK in Discrimination of colorectal polyps and CRC Groups
Table (34):	Comparison between the functional and organic Groups as Regard CEA,CA19-9, plasma M2 PK, stool analysis and FOBT 154
Table (35):	Diagnostic performance of CEA, Plasma M2-PK and FOBT in Discrimination of functional and organic Groups